Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT00191568
- Locations
- 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) MON-FRI 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Pierre Benite, France
Effects of Teriparatide on Distal Radius Fracture Healing
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-10-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT00190944
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linkoping, Sweden
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-09-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT00191373
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morgantown, West Virginia, United States
A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-08-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT00192062
- Locations
- 🇪🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Giza, Egypt
A Trial for Patients With Gestational Trophoblastic Disease
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-08-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00190918
- Locations
- 🇺🇸
Gynecologic Oncology Group 215-854-0770, Philadelphia, Pennsylvania, United States
Molecular Profiling in Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT00191308
- Locations
- 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland
Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 226
- Registration Number
- NCT00191698
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edinburgh, United Kingdom
Enzastaurin for Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT00192114
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden
Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT00191295
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Wakayama, Japan
Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 500
- Registration Number
- NCT00190827
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 or 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician, Quebec, Canada
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 OR 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician, Barcelona, Spain